Weston Family Acquires Pharmacy Chain Boots
The $8.9 billion deal ends a 20-year management era, requiring operators to watch for shifts in the retailer's inventory strategy.
Updated on Oct. 25, 2026 in Healthcare
Live Poll
Do you believe private equity ownership of major local retail chains is good for your community?
The Canadian branch of the Weston family has acquired the 177-year-old pharmacy and beauty chain Boots for $8.9 billion. The deal marks the end of a 20-year involvement by executive Stefano Pessina.
Why it matters
Operators should note the consolidation of this high-turnover pharmacy retail model, which recently benefited from strong sales in beauty products and demand for weight-loss medications.
The $8.9 billion acquisition price falls short of the $10 billion sellers initially targeted. By 2023, the global business turnover reached $140 billion, following years of expansion that included an £11 billion private buyout in 2007.
The players
Stefano Pessina
An 85-year-old executive whose 20-year strategy of massive mergers and de-mergers built a global pharmacy platform with $140 billion in turnover.
Boots
A 177-year-old pharmacy and beauty chain headquartered in Nottingham that serves as a primary retail destination in Britain.
Weston family
The Canadian business group that acquired the Boots chain following the failure of a 2024 re-float attempt.
The details
The transaction concludes a volatile period of corporate restructuring for the pharmacy chain, which moved from public ownership to private, then merged with Walgreens in 2012. The business regained momentum recently through the retail resurgence of beauty categories and the integration of weight-loss pharmaceutical products. Ownership shifts follow the abandonment of a planned 2024 initial public offering that sought to re-float the chain on public markets.
Timeline
1997: Stefano Pessina acquired Unichem to scale operations in Britain.
2007: Pessina took Boots private with KKR for £11 billion.
2012: The business announced merger plans with Walgreens.
2024: The company dropped its planned re-float on public markets.
- 2026-10-25
Publication of the article regarding the Boots sale.
Market Landscape
This acquisition updates the long-term consolidation trajectory initiated by the 2012 merger of Alliance Boots with Walgreens. It represents a final divestment of the pharmacy retail asset by its architect, marking a pivot away from the previous cross-border integration strategy.
Operators in the retail pharmacy sector should monitor how new ownership adjusts inventory strategies, particularly regarding high-growth categories like beauty and weight-loss drugs. Competitive analysis should account for the new capital backing of this legacy chain following its failed 2024 re-float.
The takeaway
Large-scale retail chains often experience shifting strategic priorities when long-term leadership exits following a failed public offering. Review internal supply chain contracts for pharmacy-adjacent beauty products to ensure pricing remains competitive during potential store-level inventory adjustments.
Further reading
For more on the changing business models within retail pharmacy, explore our Healthcare sector analysis.
Source note: This article includes information reported by MoneyWeek.
Live Poll
Do you believe private equity ownership of major local retail chains is good for your community?
